Abeona Therapeutics Inc. (ABEO) — Earnings Call X-Ray
Our AI read all 22 of ABEO's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
B
Q4 2024
Calls Analyzed
22
2016–2025
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-16
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of ABEO's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
B
Q4 2024 earnings call
2025-03-20
move ±9.3%
Management gave no formal guidance against accelerating demand. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Demand: acceleratingBacklog: growingPricing: stableHeadcount: growingCapex: increasing 5 analysts · 9 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
4 more research questions answered NO
B
Q3 2023 earnings call
2023-11-16
move ±12.6%
Management gave no formal guidance against accelerating demand. The delivery was rich in specifics, relaxed under questioning, promotional in tone.
Demand: acceleratingPricing: raisingHeadcount: growingCapex: increasing 3 analysts · 7 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
B+
Q2 2023 earnings call
2023-08-12
move ±12%
Management gave no formal guidance against contracting margins. The delivery was rich in specifics, relaxed under questioning.
Margins: contractingHeadcount: growingCapex: flat 4 analysts · 9 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q1 2023 earnings call
2023-05-24
move ±10.1%
Management gave no formal guidance. The delivery was rich in specifics.
Pricing: stable 3 analysts · 7 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q1 2022 earnings call
2022-05-17
move ±21.1%
Management gave no formal guidance against contracting margins. The delivery was unusually candid, rich in specifics.
Margins: contractingHeadcount: cuttingCapex: decreasing 2 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q1 2021 earnings call
2021-05-25
move ±25.7%
Management gave no formal guidance. The delivery was unusually candid, rich in specifics.
Headcount: growing 3 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q4 2020 earnings call
2021-03-25
move ±16.3%
Management gave no formal guidance against accelerating demand. The delivery was rich in specifics.
Demand: acceleratingHeadcount: growing 4 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q2 2019 |
2019-08-12 |
D |
none | unclear | contracting |
5/9 |
3/9 |
| Q1 2019 |
2019-05-14 |
D |
none | unclear | contracting |
6/9 |
4/9 |
| Q4 2018 |
2019-03-19 |
D |
none | unclear | contracting |
6/9 |
4/9 |
| Q3 2018 |
2018-11-12 |
C |
none | unclear | contracting |
6/9 |
3/9 |
| Q2 2018 |
2018-08-10 |
F |
none | unclear | contracting |
5/9 |
4/9 |
| Q1 2018 |
2018-05-14 |
D |
none | unclear | unclear |
6/9 |
3/9 |
| Q4 2017 |
2018-03-27 |
F |
none | unclear | contracting |
5/9 |
6/9 |
| Q3 2017 |
2017-11-20 |
D |
none | accelerating | unclear |
6/9 |
3/9 |
| Q2 2017 |
2017-08-22 |
C |
none | unclear | contracting |
6/9 |
3/9 |
| Q4 2016 |
2017-04-10 |
D |
none | unclear | unclear |
5/9 |
2/9 |
| Q3 2016 |
2016-11-18 |
D |
none | unclear | unclear |
6/9 |
4/9 |
| Q2 2016 |
2016-08-17 |
C |
none | unclear | unclear |
6/9 |
3/9 |
| Q1 2016 |
2016-05-17 |
C+ |
none | unclear | unclear |
6/9 |
2/9 |
| Q4 2015 |
2016-03-09 |
D |
none | unclear | unclear |
6/9 |
2/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of ABEO's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
F
Q4 2017 earnings call
2018-03-27
1 more research questions answered NO
C
Q2 2016 earnings call
2016-08-17
7 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← ABDNF All “A” companies
ABEV →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.